EDG-15400
Asset
Selective cardiac sarcomere modulator designed to treat heart failure with preserved ejection fraction
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2Heart failure with preserved ejection fraction
Phase 2, Recruiting, NCT07795814, clinicaltrials.gov, 16 Oct 2026
HFpEF
Phase 2, prnewswire.com, 8 Oct 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors4
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.